PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 139 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.23 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $40,115,000 | +62.4% | 1,172,943 | -15.9% | 0.84% | +74.5% |
| Q3 2021 | $24,702,000 | -59.6% | 1,394,000 | +2.3% | 0.48% | -55.6% |
| Q2 2021 | $61,162,000 | +87.6% | 1,362,790 | +8.3% | 1.09% | +58.5% |
| Q1 2021 | $32,603,000 | +17.2% | 1,258,790 | -8.8% | 0.68% | +24.5% |
| Q4 2020 | $27,820,000 | +20.6% | 1,379,971 | +16.9% | 0.55% | -2.1% |
| Q3 2020 | $23,068,000 | +28.9% | 1,179,971 | +16.4% | 0.56% | +7.9% |
| Q2 2020 | $17,898,000 | +282.4% | 1,013,495 | +350.4% | 0.52% | +183.2% |
| Q4 2017 | $4,680,000 | – | 225,000 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |